A group of six investors from the Baltic Business Angels Schleswig-Holstein e.V. has invested in the Israeli MedTech startup NYX Technologies Ltd., which specializes in AI-driven neurostimulation for chronic insomnia and neurological conditions.

Target Information

NYX Technologies Ltd., an Israeli MedTech startup, offers innovative, non-pharmacological solutions for patients suffering from chronic insomnia and associated health issues. Additionally, the company focuses on assisting patients with Parkinson's disease and cancer. The core of NYX Technologies' offering is a wearable device that utilizes EEG sensors to provide AI-driven neurostimulation. Patients can activate the device through a dedicated app before going to sleep, which allows the AI to analyze brain activity, administer stimulation, and continuously adjust the stimulation throughout the night based on real-time data.

This intelligent, non-invasive approach is currently in the final phase of clinical trials in the United States and will soon be made accessible in Germany. Healthcare providers are able to monitor treatment progress remotely, enabling timely intervention when necessary, thus enhancing patient care.

Industry Overview in Germany

The MedTech industry in Germany is one of the largest and most innovative sectors in the healthcare market, characterized by a strong focus on research and development. Germany benefits from a well-established healthcare system and is home to numerous